{"id":2157,"date":"2026-07-25T08:15:00","date_gmt":"2026-07-25T12:15:00","guid":{"rendered":"https:\/\/www.insilens.com\/?p=2157"},"modified":"2026-07-25T15:14:26","modified_gmt":"2026-07-25T19:14:26","slug":"icotyde-advances-toward-european-approval","status":"publish","type":"post","link":"https:\/\/www.insilens.com\/?p=2157","title":{"rendered":"Icotyde Advances Toward European Approval"},"content":{"rendered":"

\"\"<\/p>\n

Company<\/strong><\/p>\n

Johnson & Johnson (Janssen-Cilag International)<\/p>\n

Event Type<\/strong><\/p>\n

Regulatory Milestone (Positive CHMP Opinion)<\/p>\n

Modality<\/strong><\/p>\n

Oral Macrocyclic Peptide (IL-23 Receptor Antagonist)<\/p>\n

Asset<\/strong><\/p>\n

Icotyde (icotrokinra)<\/p>\n

Target<\/strong><\/p>\n

IL-23 Receptor<\/p>\n

Disease Area<\/strong><\/p>\n

Moderate-to-Severe Plaque Psoriasis<\/p>\n

Summary<\/h4>\n

Europe’s medicines committee recommended Icotyde, or icotrokinra, for adults and adolescents aged 12 years and older weighing at least 40 kilograms with moderate-to-severe plaque psoriasis. The July 24 opinion covers a once-daily oral peptide that directly blocks the IL-23 receptor and would become the first oral medicine targeting the IL-23 pathway in the European Union. The recommendation is based on four phase 3 trials involving approximately 2,500 patients and follows U.S. approval in March. European Commission authorization remains pending.<\/p>\n

The committee adopted a positive opinion for Icotyde in adults and adolescents aged at least 12 years and weighing at least 40 kilograms with moderate-to-severe plaque psoriasis.<\/p>\n

Across three pivotal studies, 50% to 57% of treated patients achieved PASI 90 at week 16 versus 1% to 4% with placebo. Clear or almost-clear skin was achieved by 65% to 71% versus 8% to 11% with placebo.<\/p>\n

A fourth phase 3 study evaluated difficult-to-treat scalp, genital, hand, and foot disease. The regulator described a favorable safety profile; fungal infections, reported in 1.1% of patients, were the most common adverse effect highlighted.<\/p>\n

The positive opinion is not final marketing authorization. It now proceeds to the European Commission for an EU-wide decision, after which pricing and reimbursement will be determined nationally.<\/p>\n

Modality and Mechanism<\/h4>\n

Icotrokinra is a targeted oral macrocyclic peptide that binds the IL-23 receptor and inhibits IL-23 signaling in T cells. It seeks to reproduce the pathway precision associated with injectable IL-23 biologics in an oral, once-daily format.<\/p>\n

The modality is strategically important because conventional oral small molecules can struggle to disrupt large protein-protein interfaces selectively, while peptides historically face gastrointestinal stability and absorption constraints. Clinical and regulatory success validates an orally delivered peptide as a systemic immunology modality.<\/p>\n

Clinical Positioning<\/h4>\n

Week-16 skin-clearance rates show large placebo-adjusted effects and support systemic efficacy. The principal commercial question is not placebo performance but differentiation versus injectable IL-23 antibodies, oral deucravacitinib, TYK2 competitors, and established biologics on efficacy, durability, safety, adherence, and convenience.<\/p>\n

An oral option may attract patients reluctant to inject or those stepping beyond topical therapy. Food-timing instructions, daily adherence, access, and payer sequencing could reduce the practical convenience advantage relative to infrequently dosed biologics.<\/p>\n

Regulatory Interpretation<\/h4>\n

The positive CHMP opinion substantially de-risks European authorization but is an intermediate regulatory action. It should not be described as EU approval until the European Commission adopts a legally binding decision.<\/p>\n

The four-study package and adolescent inclusion support broad positioning. Final product information, risk-management requirements, and reimbursement decisions will determine the usable label and commercial reach in individual member states.<\/p>\n

Strategic and Partnership Implications<\/h4>\n

Icotrokinra was jointly discovered under the collaboration between Protagonist Therapeutics and Janssen Biotech. Johnson & Johnson holds worldwide development and commercialization rights, giving the program both platform-validation value for oral peptides and product value in a large immunodermatology market.<\/p>\n

U.S. approval followed by a positive European opinion builds geographic launch momentum and can support further development in IL-23-mediated diseases. Success in psoriasis does not guarantee efficacy in ulcerative colitis or other tissues, where exposure and disease biology differ.<\/p>\n

Company and Product Background<\/h4>\n

Plaque psoriasis is a chronic immune-mediated skin disease driven in part by the IL-23\/Th17 axis. Moderate-to-severe disease may require phototherapy or systemic treatment, including biologic antibodies and oral immune modulators.<\/p>\n

Icotyde, or icotrokinra, was previously designated JNJ-77242113, JNJ-2113, and PN-235. It is a once-daily oral IL-23-receptor antagonist jointly discovered through the Protagonist-Janssen collaboration and developed globally by Johnson & Johnson.<\/p>\n

Signal Extraction<\/h4>\n
    \n
  • Modality validation: first oral IL-23-pathway medicine recommended in the European Union.<\/li>\n
  • Phase 3 scale: four studies and approximately 2,500 patients.<\/li>\n
  • Week-16 efficacy: PASI 90 in 50%-57% and clear\/almost-clear skin in 65%-71%.<\/li>\n
  • Regulatory boundary: European Commission authorization and national reimbursement remain pending.<\/li>\n<\/ul>\n

    InSilens Take<\/h4>\n

    Icotyde is more than another psoriasis entrant: it validates targeted oral peptides as a clinically useful way to modulate an extracellular cytokine receptor. That could expand the druggable design space between antibodies and conventional small molecules.<\/p>\n

    The near-term question is commercial differentiation rather than basic efficacy. Adoption will depend on whether patients and payers value oral delivery enough to offset daily adherence and whether real-world durability approaches that of infrequently dosed IL-23 biologics.<\/p>\n

    Signal Assessment<\/h4>\n

    Signal strength:<\/strong> 4\/5 \u2014 High. Importance:<\/strong> High \u2014 the opinion advances a first-in-modality oral peptide toward EU authorization and adds a major regulatory geography after U.S. approval. Confidence:<\/strong> High for the CHMP opinion, proposed population, mechanism, and summarized phase 3 results; medium for European commercial uptake because final authorization, national reimbursement, and comparative real-world performance remain unresolved.<\/p>\n","protected":false},"excerpt":{"rendered":"

    Europe’s medicines committee recommended Icotyde, or icotrokinra, for adults and adolescents aged 12 years and older weighing at least 40 kilograms with moderate-to-severe plaque psoriasis. The July 24 opinion covers a once-daily oral peptide…<\/p>\n","protected":false},"author":1,"featured_media":2173,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1,11,3],"tags":[79,187],"class_list":["post-2157","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-all-categories","category-clinical","category-therapeutic-indication","tag-johnson-johnson","tag-plaque-psoriasis"],"blocksy_meta":[],"_links":{"self":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/2157","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=2157"}],"version-history":[{"count":2,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/2157\/revisions"}],"predecessor-version":[{"id":2184,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/2157\/revisions\/2184"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/media\/2173"}],"wp:attachment":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=2157"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=2157"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=2157"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}